Dr. med. Hugo Lanz’s Post

As part of HeartFlow’s commitment to investing in clinical evidence, we are excited to announce the expansion of the DECIDE Registry to ~20,000 patients across ~40 sites, now including asymptomatic patients and those with prior PCI. As the largest prospective study of its kind, the DECIDE Registry will provide crucial multi-site, real-world data to understand how HeartFlow Plaque Analysis influences medical management decisions and clinical outcomes for those with suspected coronary artery disease. Together, we’re paving the way to improved patient outcomes through enhanced insights and more personalized cardiovascular disease care: https://bit.ly/4dVH8fC. #HeartFlow #DECIDERegistry #HeartFlowPlaqueAnalysis #Plaque

🔥New science alert! How do adult congenital heart disease (ACHD) patients do on the national heart transplant waitlist compared to non-ACHD patients? 🫀 Armaan Akbar, a medical student at Johns Hopkins, and his colleagues set out to answer this question in their retrospective analysis of United Network for Organ Sharing (UNSO) data, which is now out in the Journal of Cardiac Failure! The authors found that ACHD patients are listed at a lower initial priority status, have longer wait times overall, have longer wait times to final status upgrade, and have higher mortality at the same final priority status. Overall, these patients have to rely on priority status upgrades to get a heart transplant and often get upgraded too late. Read more about this in our ISHLT-simultaneous publication: https://bit.ly/3Uer3d7 #ISHLT2024

There is little question but this diagnosis awaits many of the future generation as SARS-Cov-2 proteins operate mechanistically as HIV's Nef and Tat. SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels https://lnkd.in/gjgD_mdd "33. Collins, K. L., Chen, B. K., Kalams, S. A., Walker, B. D. & Baltimore, D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391, 397–401 (1998)." SARS-CoV-2 targets ribosomal RNA biogenesis https://lnkd.in/enyFhbUq "Finally, the Tat protein of human immunodeficiency virus interacts with FBL and U3 snoRNA, impairing prerRNA processing and depleting mature ribosomes."

Delighted to work on this review discussing the role of Lipoprotein(a) reduction in cardiovascular disease published in the Journal of Clinical Medicine. Lipoprotein(a) is six times more atherogenic than LDL cholesterol on a per-particle basis, is largely genetically determined and a risk factor for coronary heart disease and aortic valve stenosis. There are currently no approved drugs for lipoprotein(a) reduction in clinical practice, but a number of clinical trials are ongoing. Pelacarsen is undergoing phase 3 clinical trials (Lp(a) HORIZON) with earlier trial data showing a dose-dependent reduction in lipoprotein(a) between 35-80%.

Published today, Clinical Management and Transplant Considerations in Pediatric Pulmonary Hypertension Due to Left Heart Disease: A Scientific Statement from the American Heart Association. In pulmonary hypertension due to left heart disease, the primary driver is systolic or diastolic dysfunction of the left ventricle, leading to left atrial hypertension and pulmonary venous congestion. Over time, the pulmonary arterial bed may remodel, causing elevated pulmonary vascular resistance. http://spr.ly/6044Qyg7r. 📷 Mechanisms of pulmonary hypertension due to left heart disease

Ready to up-skill in ECG analysis and interpretation? 💓atrial fibrillation 💓ischaemic heart disease 💓valve disease 💓heart failure This 3 hour course aims to improve your confidence in the diagnosis and management of important cardiology conditions in primary care. Presented by Dr Nick Jones, join us on 27th April. #PrimaryCare #ECG #HeartDisease

Today, our Executive Director, Neil Johnson, proudly presented an e-poster at the European Society of Cardiology’s Congress in London on Global Heart Hub’s patient-led study, Insights from Patients living with Elevated Cholesterol (IPEC).    It is a tremendous achievement to have the patient perspective included at such a prestigious international scientific meeting.   The IPEC e-poster focuses on the importance of the first discussion between a patient and their healthcare professional after diagnosis of hypercholesterolemia and how that interaction could help change the course of atherosclerotic cardiovascular disease (#ASCVD), the leading cause of mortality worldwide.     View our ESC poster now - https://lnkd.in/gm2AqrPn #ESCCongress #IPEC #PatientInsights #LDLCholesterol

A 40-year-old man presents to the clinic with worsening shortness of breath and a persistent dry cough for the past several months. He reports significant fatigue and mild chest discomfort, particularly on the left side. He denies fever, hemoptysis, or night sweats. His medical history is significant for Hodgkin's Disease, which was treated 15 years ago with chemotherapy and radiation therapy to the left hilar region. He has no history of smoking, and there is no family history of pulmonary disease. Physical examination: Vital signs: Temperature 98.6°F Blood pressure 125/80 mm Hg Pulse 95/min Respiratory rate 22/min Oxygen saturation 92% on room air Auscultation: Decreased breath sounds and a dull percussion note over the left hemithorax, with inspiratory crackles noted in the left lung base. No jugular venous distension or peripheral edema is observed. Laboratory findings include: Arterial Blood Gas (ABG) on room air: pH 7.43 PaCO2 37 mm Hg PaO2 68 mm Hg Complete Blood Count: Hemoglobin 14.0 g/dL White blood cell count 6,800/mm³ Pulmonary Function Tests: Reduced forced vital capacity (FVC) Reduced total lung capacity (TLC) Reduced diffusing capacity of the lungs for carbon monoxide (DLCO) A chest x-ray is attached. Which of the following is the most likely diagnosis? A) Radiation-Induced Pulmonary Fibrosis B) Idiopathic Pulmonary Fibrosis C) Pulmonary Embolism Please like, follow, share, repost, and comment if you like my content. I try my best to respond to every comment personally. If you want to see all of my future posts, hit the bell icon next to my profile.

At the Structural Heart Disease Program and Cardiac Cath Lab at Advocate Christ Medical Center, we are proud to provide a comprehensive range of large-bore percutaneous mechanical aspiration and thrombectomy procedures. Recent evidence demonstrated the effectiveness of percutaneous mechanical aspiration in managing a variety of complex clinical scenarios. Here are examples of large-bore mechanical aspiration cases we did in the last few weeks, including infective endocarditis, submassive—and massive—pulmonary embolism, intracardiac thrombi and tumors, and pacemaker lead infection. #StructuralHeartDisease #InterventionalCardiology #Peerlesstrial #MechanicalAspiration #Thrombectomy #PulmonaryEmbolism #InfectiveEndocarditis #CardiologyInnovation #Fibroelastoma #HealthcareExcellence #AdvocateHealth #Inari #AlphaVac #Penumbra #4DICE

Did you know that cardiovascular disease is the leading cause of death worldwide? High blood pressure, a critical risk factor for cardiovascular disease, affects 1.13 billion people globally. However, only 20% of those with high blood pressure have it under control, and about half are unaware they have it. Remote patient monitoring can help bridge this care gap, enabling early diagnosis and avoiding preventable deaths. Learn more from Dr. Alexander Blood, MD, MSc, FACC, Cardiologist and Associate Director of Clinical Transformation at Mass General Brigham Hospital, as he explores the critical role of remote patient monitoring in the early detection and management of chronic conditions like cardiovascular disease. With consistent patient engagement, proper device education and the facilitation of patient-clinical team collaboration, care teams receive more accurate information to better manage chronic conditions. 📖 Read the full article: https://bit.ly/49wFuiX